GSK boosts respiratory portfolio with $1.4 billion Aiolos Bio deal
Reuters
Published Jan 09, 2024 07:08
Updated Jan 09, 2024 16:25
(Reuters) -GSK on Tuesday said it would acquire asthma drug maker Aiolos Bio in a deal worth up to $1.4 billion, as the British drugmaker boosts its growing respiratory diseases portfolio.
Founded in 2023, Aiolos is focused on developing therapies for respiratory and inflammatory conditions. It is currently developing 'AIO-001', a treatment for asthma which is ready to enter mid-stage clinical trials.
The drug would expand the reach of its current respiratory biologics portfolio, including to the 40% of severe asthma patients with certain conditions, where treatment options are still needed, said Tony Wood, GSK's chief scientific officer.
GSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone payments as well as pay tiered royalties to China's Hengrui Pharma, which licensed the asthma therapy to Aiolos.
GSK's respiratory diseases portfolio, which is currently growing on the back of a strong launch of its respiratory syncytial virus (RSV) vaccine, has been a focus for the company as it grapples with a combination of patent expiries and declining revenue from its current bestsellers by the end of this decade.
Respiratory medicines and vaccines generated about 11 billion pounds ($14 billion) in sales for GSK in 2022.
($1 = 0.7845 pounds)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.